How to Buy Into Human Longevity Stock via Public Companies

The genomics sector has been on a whirlwind journey in the past year. CRISPR gene cutting technology earned two women the Nobel Prize in chemistry in 2020. One company called Human Longevity, Inc. has a different approach to research, but it's still on investors' minds.  

Human Longevity is involved with one of the stock market's trendiest genomics buys. Here's how retail investors can get in.

According to the company's website, Human Longevity "combines state-of-the-art DNA sequencing and expert analysis with machine learning, to help change medicine to a more data-driven science."

The company is led by a doctoral duo, executive chairman Wei-Wu He, Ph.D., and chief investment officer David Karow, M.D., Ph.D. They have the largest collection of data on the genomic and phenotypic fronts.

Human Longevity's main offering is something called HLIQ Whole Genome, which is a report that effectively compares a patient’s DNA to the company's database to garner information about their condition.

Ultimately, Human Longevity's goal is to use the data to propel discoveries for treatment and health plans that can lengthen lifespans and improve people's quality of life. Not all companies in the genomics industry have such a broad goal.

NeoGenomics, Inc. boasts the largest portfolio of cancer diagnostic testing in the U.S. The company trades under the ticker symbol "NEO" on the Nasdaq Exchange. Historically, NeoGenomics has spent a lot of money and time on acquiring and integrating labs that align with its mission. This includes subsidiaries like Clarient and Genoptix, as well as a portion of Human Longevity, specifically its oncological assets. 

While Human Longevity isn't publicly traded on its own, investors can inject capital for their success using NeoGenomics as a vehicle. It's a safer bet anyway with its massive reach — namely a $6.42 billion market capitalization as of Jan. 21.

Human Longevity also partners with AstraZeneca. Right now, the companies are in the midst of a ten-year agreement that started in 2016. The agreement gives Human Longevity access to DNA sequencing data from AstraZeneca's clinical trials. 

AstraZeneca trades under the ticker symbol "AZN" on the NYSE and the London Stock Exchange.

Right now, Human Longevity is retaining its position as a private company. However, it's possible that the company continues to expand its network of noteworthy partnerships with publicly traded companies. 

NeoGenomics stock has risen more than 70 percent in the past 12 months, even including the market-wide crash that occurred from February to March 2020. A healthy 7.67 percent of that growth occurred this week. Meanwhile, AstraZeneca stock has retained its base despite pandemic-induced implications and vaccine hurdles. This week alone, AZN rose as much as 2.86 percent, which isn't dramatic but it's a whole lot better than being in the red.